Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction

E. Magnus Ohman, Robert M. Califf, Eric J. Topol, Richard Candela, Charles Abbottsmith, Stephen Ellis, Kristina N. Sigmon, Dean Kereiakes, Barry George, Richard Stack

Research output: Contribution to journalArticle

413 Citations (Scopus)

Abstract

To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88% of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65% versus 44%, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus 10%, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99% for reoccluded (value, 90/100%) compared with 95% for patent (value, 80/99%). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p=0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median Δ ejection fraction was -2 compared with 1 (p=0.006) and median Δ infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p=0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p=0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery.

Original languageEnglish
Pages (from-to)781-791
Number of pages11
JournalCirculation
Volume82
Issue number3
StatePublished - Sep 1 1990
Externally publishedYes

Fingerprint

Reperfusion
Myocardial Infarction
Arteries
Thrombolytic Therapy
Therapeutics
Urokinase-Type Plasminogen Activator
Mortality
Diltiazem
Nitroglycerin
Tissue Plasminogen Activator
Hospital Mortality
Left Ventricular Function
Stroke Volume
Aspirin
Heparin
Coronary Vessels
Angiography
Pathologic Constriction
Morbidity

Keywords

  • Clinical trials
  • Diltiazem
  • Heparin
  • Left ventricular function
  • Mortality
  • Myocardial infarction
  • Nitroglycerin
  • Patency
  • Thrombolysis
  • Tissue-type plasminogen activator
  • Urokinase

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Ohman, E. M., Califf, R. M., Topol, E. J., Candela, R., Abbottsmith, C., Ellis, S., ... Stack, R. (1990). Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation, 82(3), 781-791.

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. / Ohman, E. Magnus; Califf, Robert M.; Topol, Eric J.; Candela, Richard; Abbottsmith, Charles; Ellis, Stephen; Sigmon, Kristina N.; Kereiakes, Dean; George, Barry; Stack, Richard.

In: Circulation, Vol. 82, No. 3, 01.09.1990, p. 781-791.

Research output: Contribution to journalArticle

Ohman, EM, Califf, RM, Topol, EJ, Candela, R, Abbottsmith, C, Ellis, S, Sigmon, KN, Kereiakes, D, George, B & Stack, R 1990, 'Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction', Circulation, vol. 82, no. 3, pp. 781-791.
Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990 Sep 1;82(3):781-791.
Ohman, E. Magnus ; Califf, Robert M. ; Topol, Eric J. ; Candela, Richard ; Abbottsmith, Charles ; Ellis, Stephen ; Sigmon, Kristina N. ; Kereiakes, Dean ; George, Barry ; Stack, Richard. / Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. In: Circulation. 1990 ; Vol. 82, No. 3. pp. 781-791.
@article{164996571f45493a8026968f16433632,
title = "Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction",
abstract = "To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88{\%} of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4{\%}), and 58{\%} of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65{\%} versus 44{\%}, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21{\%} versus 10{\%}, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99{\%} for reoccluded (value, 90/100{\%}) compared with 95{\%} for patent (value, 80/99{\%}). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p=0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median Δ ejection fraction was -2 compared with 1 (p=0.006) and median Δ infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p=0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0{\%} versus 4.5{\%}, respectively; p=0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery.",
keywords = "Clinical trials, Diltiazem, Heparin, Left ventricular function, Mortality, Myocardial infarction, Nitroglycerin, Patency, Thrombolysis, Tissue-type plasminogen activator, Urokinase",
author = "Ohman, {E. Magnus} and Califf, {Robert M.} and Topol, {Eric J.} and Richard Candela and Charles Abbottsmith and Stephen Ellis and Sigmon, {Kristina N.} and Dean Kereiakes and Barry George and Richard Stack",
year = "1990",
month = "9",
day = "1",
language = "English",
volume = "82",
pages = "781--791",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction

AU - Ohman, E. Magnus

AU - Califf, Robert M.

AU - Topol, Eric J.

AU - Candela, Richard

AU - Abbottsmith, Charles

AU - Ellis, Stephen

AU - Sigmon, Kristina N.

AU - Kereiakes, Dean

AU - George, Barry

AU - Stack, Richard

PY - 1990/9/1

Y1 - 1990/9/1

N2 - To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88% of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65% versus 44%, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus 10%, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99% for reoccluded (value, 90/100%) compared with 95% for patent (value, 80/99%). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p=0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median Δ ejection fraction was -2 compared with 1 (p=0.006) and median Δ infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p=0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p=0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery.

AB - To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88% of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65% versus 44%, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus 10%, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99% for reoccluded (value, 90/100%) compared with 95% for patent (value, 80/99%). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p=0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median Δ ejection fraction was -2 compared with 1 (p=0.006) and median Δ infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p=0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p=0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery.

KW - Clinical trials

KW - Diltiazem

KW - Heparin

KW - Left ventricular function

KW - Mortality

KW - Myocardial infarction

KW - Nitroglycerin

KW - Patency

KW - Thrombolysis

KW - Tissue-type plasminogen activator

KW - Urokinase

UR - http://www.scopus.com/inward/record.url?scp=0025118412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025118412&partnerID=8YFLogxK

M3 - Article

C2 - 2394002

AN - SCOPUS:0025118412

VL - 82

SP - 781

EP - 791

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -